More than half a dozen major drugmakers are participating in the Trump administration's speedier review program for new ...

All 16 drug companies that inked deals with the Trump administration over the past few months still raised some of their ...

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings ...

We recently published 10 Stocks Jim Cramer Talked About . Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer talked ...

After an agency review, the FDA asked drugmakers to remove warnings about a potential risk of suicidal thoughts from widely ...

Exelixis may only have one drug on the market right now, but with phase 3 results for a potential new blockbuster on the ...

Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) moved to tighten its grip on one of biotech’s hottest disease ...

The U.S. Food and Drug Administration has delayed reviews of two drugs chosen for the Trump administration's new fast-track ...

Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on ...

A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been ...